In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Time Is Money
ICON’s Andy Smith discusses the role of duration in the valuation of early-stage biopharma assets in this In Vivo article.
-
Proving Real World Value
In the July/Aug 2017 issue of PME, Ramita Tandon discusses how to usereal world intelligenceto demonstrate drug efficacy and cost-effectiveness.
-
Domestic Research Enhancement Act Changing Clinical Trials Outsourcing
This article includes commentary from Steve Cutler on US healthcare policy and its effect onclinical trial outsourcing.
-
The Burden of Choice
Dr. Martin Lachs, Dr. Reinhard Eisebitt and Dr. Valerii Fedorov contribute to this article in Clinical Oncologist Daily on ICON's decision to invest in a Cancer Moonshot project using quantum computing.
-
ICON Oncology’s Opinion of How We Can Reach for the Stars With a Moonshot
Dr. Martin Lachs, Dr. Reinhard Eisebitt and Dr. Valerii Fedorov contribute to this article in Clinical Oncologist Daily on ICON's decision to invest in a Cancer Moonshot project using quantum computing.
-
APAC is the fastest growing market for CRO industry
In this article, Mary Pan outlines the growth and trends of clinical trials in the APAC region.
-
Effective Sponsor-CRO Collaboration
In this PharmaVOICE article, read commentary from Dr. Phil Birch on effectivesponsor-CRO collaboration.
-
ICON Recognised for Excellence in Vaccine Development
Coverage of ICON's recent award at the ViE Awards. these awards honor individuals and organisations that continually set standards of excellence and have made outstanding achievements in the vaccine industry.
-
Predatory Journals Are Back in the Firing Line
Learn how to spot apredatory journalwith these tips from PubsHub.
-
Overcoming Four Challenges to Successful Rare Disease Drug Development
ICON contributed to this article in Pharmafocus relating to overcoming four challenges to greatly improve the chances for a successful rare or “orphan” drug trial.
